当前位置: 首页 >> 检索结果
4. Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.
作者: Emil Nielsen Holck.;Niels R Holm.;David Hildick-Smith.;M Mitchell Lindsay.;Mark S Spence.;Andrejs Erglis.;Ian B A Menown.;Terje Steigen.;Lone Juul Hune Mogensen.;Ivy Susanne Modrau.;Matti Niemelä.;Jens F Lassen.;Keith Oldroyd.;Peteris Stradins.;Simon J Walsh.;Petter C Endresen.;Thor Trovik.;Ole Fröbert.;Alastair N J Graham.;Vesa Anttila.;Uday Trivedi.;Leif Thuesen.;Evald H Christiansen.
来源: Lancet. 2026年407卷10536期1374-1382页
Coronary artery bypass grafting (CABG) is recommended over percutaneous coronary intervention (PCI) for patients with significant unprotected left main coronary artery disease. We aim to provide long-term outcome data comparing PCI with newer generation drug-eluting stents and CABG, which are scarce.
5. Global burden of cancer in children and adolescents aged 0-19 years, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Information on childhood cancer burden is crucial for effective cancer policy planning. Unfortunately, observed paediatric cancer data are not available in every country, and previous global burden estimates have not discretely reported several common cancers of childhood. We aimed to inform efforts to address childhood cancer burden globally by analysing results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, which now include nine additional cancer causes compared with previous GBD analyses.
18. Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
作者: Ronak Delewi.;Hugo M Aarts.;Gijs M Broeze.;Kimberley I Hemelrijk.;Dirk Jan van Ginkel.;Geert A A Versteeg.;Maik J Grundeken.;Bimmer E P M Claessen.;Pim A L Tonino.;Carl E Schotborgh.;Martijn Meuwissen.;Gert K van Houwelingen.;Joanna J Wykrzykowska.;Giovanni Amoroso.;Tessel N Vossenberg.;Pieter A Vriesendorp.;Niels van Royen.;Jurriën M Ten Berg.;Jan G P Tijssen.;Michiel Voskuil.; .
来源: Lancet. 2026年
Coronary artery disease is common in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to assess whether deferral of percutaneous coronary intervention (PCI) is non-inferior to routine PCI before TAVI in patients with coronary artery disease.
19. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.
作者: Jeehoon Kang.;Sungjoon Park.;Han-Mo Yang.;Eun-Seok Shin.;Seung-Woon Rha.;Jang-Whan Bae.;Nam Ho Lee.;Hyuck-Jun Yoon.;Yoon Haeng Cho.;Ung Kim.;Song-Yi Kim.;Sang-Hyun Kim.;Jung-Kyu Han.;Kyung Woo Park.;Hyo-Soo Kim.; .
来源: Lancet. 2026年
The long-term clinical outcomes of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention (PCI) remain uncertain. We conducted a 10-year follow-up of the HOST-EXAM trial to assess the very long-term effects of clopidogrel versus aspirin monotherapy in this setting.
|